RxDoctor Payments Data

Bassam Assaf, MD

Neurology · Moline, ILNPI 1225009426

Payments from drug & device makers

$21,743in general payments, 2019–2025

Across 1,049 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Harmony Biosciences LLC$2K
  • SK Life Science, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Eisai Inc.$1K
  • Livanova USA, Inc.$1K
  • plus $13K from 54 others

What the payments were for

  • Speaking & faculty fees$1651%
  • Travel & lodging$4912%
  • Food & beverage$20,50494%
  • Education$5833%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)145$2,393
Harmony Biosciences LLC125$1,740
SK Life Science, Inc.48$1,234
Teva Pharmaceuticals USA, Inc.68$1,065
Eisai Inc.45$1,058
Livanova USA, Inc.11$1,028
Argenx US, Inc.41$972
Lilly USA, LLC47$810
Amneal Pharmaceuticals LLC31$748
Novartis65$710
Biogen22$624
Jazz Pharmaceuticals Inc.22$609
Johnson & Johnson(2 entities)12$606
UCB, Inc.24$604
AstraZeneca18$536
Lundbeck LLC18$462
Biohaven Pharmaceutical Holding Company Ltd.36$443
Otsuka America Pharmaceutical, Inc.15$432
Amgen20$429
Axsome Therapeutics, Inc.14$403
Pfizer22$337
MDD US Operations, LLC9$296
Sumitomo Pharma America, Inc.11$281
Neurocrine Biosciences, Inc.12$271
Bristol Myers Squibb12$269
Idorsia Pharmaceuticals US Inc20$269
Genentech USA, Inc.5$250
Sunovion Pharmaceuticals Inc.12$230
Kyowa Kirin, Inc.8$207
Upsher-smith Laboratories LLC10$203
Mallinckrodt Hospital Products Inc.9$193
Catalyst Pharmaceuticals, Inc.9$185
EMD Serono, Inc.4$183
Acadia Pharmaceuticals Inc9$180
Supernus Pharmaceuticals, Inc.11$175
TG Therapeutics, Inc.3$169
E.r. Squibb & Sons, L.L.C.4$151
Biohaven Pharmaceuticals, Inc.7$119
GE HealthCare3$72
Merz Pharmaceuticals, LLC3$69
Sanofi4$67
Acorda Therapeutics, Inc3$55
Takeda Pharmaceuticals U.S.A., Inc.3$52
CSL Behring2$46
Neurelis, Inc.2$45
Greenwich Biosciences, Inc.3$45
Currax Pharmaceuticals LLC3$42
Impel Pharmaceuticals Inc.2$41
Philips North America LLC2$41
Abbott2$34
Averitas Pharma Inc.1$33
Resmed Corp1$25
Boston Scientific1$24
Inspire Medical Systems, Inc.1$23
Cala Health, Inc.1$22
Avanir Pharmaceuticals, Inc.1$21
Corium, LLC1$21
Banner Life Sciences, LLC1$17
Ceribell, Inc.1$16
Mallinckrodt Enterprises LLC1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,743 in reported general payments places this provider in the 80th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$321,947
Medicare patients
705
Services billed
2,539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant69$93,715
Nurtec OdtRimegepant Sulfate34$67,894
QuliptaAtogepant49$64,545
RytaryCarbidopa/Levodopa40$53,112
XcopriCenobamate43$47,972
Lacosamide219$35,813
RexultiBrexpiprazole23$32,469
Aimovig AutoinjectorErenumab-Aooe22$24,239
Emgality PenGalcanezumab-Gnlm11$14,566
Levetiracetam457$13,811
Cyclosporine20$13,734
QuviviqDaridorexant Hcl17$12,244
ReyvowLasmiditan Succinate15$10,712
Gabapentin333$8,217
Dalfampridine ErDalfampridine12$5,785

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$2,393$158,259118 claims
PfizerNurtec Odt$337$67,89434 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$748$55,58467 claims
SK Life Science, Inc.Xcopri$1,234$47,97243 claims
Otsuka America Pharmaceutical, Inc.Rexulti$432$32,46923 claims
Idorsia Pharmaceuticals US IncQuviviq$269$12,24417 claims
Lilly USA, LLCReyvow$810$10,71215 claims
Upsher-smith Laboratories LLCTopiramate$203$1,592101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 790 neurology providers in Illinois.

Other neurology in Moline

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →